Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, October 26, 2014

ClinicSpeak: PML and dimethyl fumarate (Tecfidera)

October 24, 2014

How should we deal with the PML risk in patients on Tecfidera? #ClinicSpeak #MSBlog #MSResearch

"Progressive multifocal leukoencephalopathy or PML is classed as an opportunistic infection and typically occurs in patients who are immunosuppressed as a result of cancers, in particular haematological malignancies, immunosuppression from medication, or specific diseases such as HIV that are associated with immune suppression."

"The fact that Biogen-Idec reported a case of PML on their formulation of dimethyl fumarate or DMF (Tecfidera) two days ago appears to have triggered a panic response. My email inbox is full of queries from anxious patients and colleagues about what we should do."

"I have noted a spike in Google Trends when using the search terms ‘Tecfidera and PML’. The questions I have been asked are:

1. Should we treat the risk of PML on DMF in the same way do the risk on natalizumab?

Obviously not -- CLICK here to continue this read

 Keep CURRENT and up to date,
with MS Views and News - OPT-IN here

No comments: